

Paris January 20, 2021: 2021: Pherecydes-Pharma, BMSystems' first therapeutic start-up, announced its intention to List on the Euronext Growth® Market in Paris

2021 will be a great year for BMSystems. We are proud that [Pherecydes-Pharma](#), our first therapeutic start-up, announced its intention to List on the Euronext Growth® Market in Paris.

"Pour les investisseurs francophones, nous vous invitons à participer [le 21 janvier 2021 à 10h](#) à la [webconférence investisseurs](#) organisée par Pherecydes-Pharma".

For all details and legal information please visit [Pherecydes-Pharma new website](#) or directly [Pherecydes-Pharma IPO projet website](#)

*

With a world's first in neurodegenerative diseases, [1 therapeutic start-up, 1 exclusive out-license,](#) and [the launch of Telesphore-Pharma](#),

BMSystems' 2nd therapeutic start-up in 2021, this announcement confirms the excellence of BMSystems in delivering value to patients and shareholders.

Created in 2004, profitable since 2006, thanks to our recurrent clients, BMSystems addresses two complementary business targets:

- **For R&D, Translational Medicine & Digital Health Executives**, we offer *robust alternative decision-making to de-risk, save time and cost*

of R&D and Digital Health programs,

Écrit par Pherecydes-Pharma

Lundi, 25 Janvier 2021 17:39 - Mis à jour Lundi, 25 Janvier 2021 18:05

- **For Business Developers, Patients Groups & Investors**, we discover *novel low-risk, highly effective and cost-effective* diagnostic, therapy, nutrition, cosmetic, bioprocess solutions for spin-offs or out-licensing.

We warmly invite you [to visit our new website](#) to discover our achievements in diagnostics, therapeutics, cosmetics, digital-Health and bio-processes.

Do not hesitate to contact us for more information or any business request.

Best regards,

Manuel GEA

CEO Bio-Modeling Systems

* The following information does not constitute or should not be considered as a public offering, an offer to subscribe or a public solicitation in preparation for a public offering of Pherecydes Pharma's securities.

[About Bio-Modeling Systems](#)

Écrit par Pherecydes-Pharma

Lundi, 25 Janvier 2021 17:39 - Mis à jour Lundi, 25 Janvier 2021 18:05

Bio-Modeling Systems is the world's first Mechanisms-Based medicine company that changed the discovery paradigm to create novel medical meanings from unreliable heterogeneous sources of data to generate validated & directly exploitable first in class heuristic non-mathematical mechanistic CADI™ models. Bio-Modeling Systems is a 100% biology driven company focused on discovery, and critical high impact decisions making and address the following Markets: Pharma, Cosmetics, Nutrition, Health Technologies, Connected health with its dual business model: Contractual or Collaborative R&D programs.

[For all details and presentations, visit our new website](#)